JOSÉ LUIS
CABRIADA NUÑO
Investigador hasta 2022
Mutua de Terrassa
Terrassa, EspañaPublicaciones en colaboración con investigadores/as de Mutua de Terrassa (9)
2024
-
Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study
Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 727-733
-
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Pharmaceutics, Vol. 16, Núm. 5
2018
-
Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A Randomized multicentre clinical trial
Journal of Crohn's and Colitis, Vol. 12, Núm. 6, pp. 687-694
2014
-
Disease severity in familial cases of IBD
Journal of Crohn's and Colitis, Vol. 8, Núm. 3, pp. 234-239
-
Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database
Journal of Crohn's and Colitis, Vol. 8, Núm. 7, pp. 654-661
-
Risk of colectomy in patients with ulcerative colitis under thiopurine treatment
Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293
2013
-
Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de fármacos antifactor de necrosis tumoral α en la enfermedad inflamatoria intestinal (2013)
Gastroenterologia y Hepatologia, Vol. 36, Núm. 3, pp. 127-146
-
Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era
Alimentary Pharmacology and Therapeutics, Vol. 38, Núm. 7, pp. 752-760
2012
-
Long-term durability of response to adalimumab in Crohn's disease
Inflammatory Bowel Diseases, Vol. 18, Núm. 4, pp. 685-690